Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.

@article{Lee2019AssociationOD,
  title={Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.},
  author={Seon Gu Lee and Hee Jung Lee and Moon Soo Yoon and Dong Hyun Kim},
  journal={JAMA dermatology},
  year={2019},
  volume={155 2},
  pages={
          172-177
        }
}
Importance Recent studies suggest that dipeptidyl peptidase 4 (DPP-4) inhibitors are associated with an increased risk of developing bullous pemphigoid (BP). Population-based studies on the association between DPP-4 inhibitors and BP are limited. Objective To characterize the potential association between the use of DPP-4 inhibitors and an increased risk of developing BP. Design, Setting, and Participants This retrospective, nationwide, population-based, case-control study using Korean… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-2 OF 2 CITATIONS

Interested in publishing with us ? Contact book

VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

Increased prevalence of diabetes mellitus in bullous pemphigoid patients during the last decade

L Fania, G Di Zenzo, B Didona
  • J Eur Acad Dermatol Venereol
  • 2018

Increased prevalence of diabetes mellitus in bullous pemphigoid patients during the last decade

L Fania, G Di Zenzo, B Didona
  • J Eur Acad Dermatol Venereol
  • 2018